Recursion Pharmaceuticals, INC 8-K filings

Recursion Pharmaceuticals announced strong pipeline execution and platform advancements in Q2 2026, highlighted by Genentech exercising an option for a neuroscience target and positive clinical updates for REC-4881 and REC-7735.

Recursion Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the ratification of its independent auditor.

Recursion Pharmaceuticals reports Q1 2026 results with strong pipeline execution, favorable early clinical data for REC-1245, and disciplined capital management extending cash runway into early 2028.

Recursion Pharmaceuticals announced the appointment of Dr. Vicki Goodman, a seasoned oncology drug development executive, as its new Chief Medical Officer, effective April 6, 2026.

Recursion Pharmaceuticals announced positive clinical validation for its AI-driven platform in FAP, achieved a fifth Sanofi milestone, and extended its cash runway into early 2028.

Recursion Pharmaceuticals presented an updated investor presentation at the JP Morgan Healthcare Conference, highlighting progress in its AI-native drug discovery platform and clinical pipeline, including positive REC-4881 FAP data.

Recursion Pharmaceuticals announced positive Phase 1b/2 TUPELO trial data for REC-4881, demonstrating rapid and durable reductions in polyp burden for familial adenomatous polyposis patients.

Recursion Pharmaceuticals filed a prospectus supplement to register 7,088,742 Class A common shares for resale by Tempus AI, Inc., issued as payment for annual license fees.

Recursion Pharmaceuticals announced a leadership transition with Najat Khan appointed CEO, alongside reporting Q3 2025 financial results and significant partnership milestones, including a $30 million payment from Roche and Genentech.

Recursion Pharmaceuticals announced Roche's exercise of an option for its Microglia Mapa, triggering a $30 million acceptance fee.

Recursion Pharmaceuticals issued 2.4 million contingent shares to Rallybio and filed a prospectus supplement for their resale following a key milestone achievement.

Recursion Pharmaceuticals reported increased revenue and significant net losses for Q2 2025, while advancing its clinical pipeline and securing a $7 million Sanofi milestone payment.

Recursion Pharmaceuticals, Inc. has acquired full ownership of REV102, a potential first-in-class oral ENPP1 inhibitor for hypophosphatasia, from Rallybio Corporation, enhancing its pipeline with a promising preclinical asset.

Recursion Pharmaceuticals, Inc. announced that its stockholders approved all proposals at the 2025 annual meeting, including the re-election of three Class I directors, the advisory resolution on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor.

Recursion Pharmaceuticals announced a strategic workforce reduction of approximately 20% and expects to extend its cash runway into the fourth quarter of 2027, driven by a streamlined operating strategy and anticipated partnership inflows.

Recursion Pharmaceuticals filed a prospectus supplement to register the resale of 4,260,927 shares of its Class A common stock issued to Tempus Labs as payment for annual license fees.

Recursion Pharmaceuticals announced its Q1 2025 financial results, highlighting pipeline advancements, partnership achievements, and operational streamlining, extending its cash runway into mid-2027.

Recursion Pharmaceuticals appoints Elaine Sun and Dr. Namandj Bumpus to its Board of Directors, effective March 15, 2025, to bolster its leadership team.

Recursion announces positive clinical trial results, partnership milestones, and financial updates for Q4 and fiscal year 2024, highlighting its advancements as a leading TechBio company after merging with Exscientia.

Recursion Pharmaceuticals presented an updated investor presentation highlighting advancements in its pipeline and strategic collaborations at the JP Morgan Healthcare Conference.

Recursion Pharmaceuticals has filed a prospectus supplement to register for resale approximately 3.5 million shares of its Class A common stock, which were previously issued to Tempus Labs as payment for a license fee.

Recursion Pharmaceuticals has appointed Ben Taylor as Chief Financial Officer, offering a base salary, bonus, and a substantial equity package.

Recursion Pharmaceuticals has finalized its acquisition of Exscientia, with pro forma financial statements now available reflecting the combined entity.

Recursion Pharmaceuticals finalized its acquisition of Exscientia, issuing over 102 million shares of Class A common stock as part of the transaction.

Recursion Pharmaceuticals has finalized its acquisition of Exscientia, creating a combined entity poised to lead in AI-driven drug discovery and development.

Recursion Pharmaceuticals' stockholders have approved the issuance of shares for the acquisition of Exscientia.

Recursion and Exscientia have received overwhelming shareholder approval for their proposed merger, with the transaction expected to close on November 20, 2024.

Recursion Pharmaceuticals announced its third quarter 2024 financial results, highlighted by a $30 million option agreement with Roche-Genentech and progress towards its merger with Exscientia.

Recursion Pharmaceuticals and Exscientia have amended their merger agreement to include the appointment of two Exscientia board members to Recursion's board, with one additional board member to be mutually agreed upon.

Recursion Pharmaceuticals has received FDA clearance for its investigational new drug application for REC-1245, a potential first-in-class RBM39 degrader, and is also planning a merger with Exscientia.